Bedoukian   RussellIPM   RussellIPM   Piezoelectric Micro-Sprayer


Home
Animal Taxa
Plant Taxa
Semiochemicals
Floral Compounds
Semiochemical Detail
Semiochemicals & Taxa
Synthesis
Control
Invasive spp.
References

Abstract

Guide

Alphascents
Pherobio
InsectScience
E-Econex
Counterpart-Semiochemicals
Print
Email to a Friend
Kindly Donate for The Pherobase

« Previous AbstractUnderstorey Rhododendron tomentosum and Leaf Trichome Density Affect Mountain Birch VOC Emissions in the Subarctic    Next AbstractStructure and chemical organization of the accessory olfactory bulb in the goat »

Curr Opin Allergy Clin Immunol


Title:Systemic and breath biomarkers for asthma: an update
Author(s):Mogensen I; James A; Malinovschi A;
Address:"Department of Medical Sciences, Clinical Physiology. Department of Medical Sciences, Respiratory-, Allergy- and Sleep Research, Uppsala University, Uppsala. Institute of Environmental Medicine, Department of Experimental Asthma and Allergy Research. Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden"
Journal Title:Curr Opin Allergy Clin Immunol
Year:2020
Volume:20
Issue:1
Page Number:71 - 79
DOI: 10.1097/ACI.0000000000000599
ISSN/ISBN:1473-6322 (Electronic) 1473-6322 (Linking)
Abstract:"PURPOSE OF REVIEW: Finding suitable biomarkers to phenotype asthma, identify individuals at risk of worsening and guide treatment is highly prioritized in asthma research. We aimed to provide an analysis of currently used and upcoming biomarkers, focusing on developments published in the past 2 years. RECENT FINDINGS: Type 2 inflammation is the most studied asthma mechanism with the most biomarkers in the pipeline. Blood eosinophils and fractional exhaled nitric oxide (FeNO) are those most used clinically. Recent developments include their ability to identify individuals at higher risk of exacerbations, faster decline in lung function and more likely to benefit from anti-IL-5 and anti-IL-4/-13 treatment. Certain patterns of urinary eicosanoid excretion also relate to type 2 inflammation. Results of recent trials investigating the use of serum periostin or dipeptidyl peptidase-4 to guide anti-IL-13 therapy were somewhat disappointing. Less is known about non-type 2 inflammation but blood neutrophils and YKL-40 may be higher in patients with evidence of non-type 2 asthma. Volatile organic compounds show promise in their ability to distinguish both eosinophilic and neutrophilic asthma. SUMMARY: The ultimate panel of biomarkers for identification of activated inflammatory pathways and treatment strategies in asthma patients still lies in the future, particularly for non-type 2 asthma, but potential candidates are available"
Keywords:"Animals Asthma/*diagnosis Biomarkers/*blood Breath Tests Cytokines/*blood Diagnosis, Differential Eosinophils/*pathology Exhalation Humans Neutrophils/*pathology Nitric Oxide/*metabolism Th2 Cells/immunology;"
Notes:"MedlineMogensen, Ida James, Anna Malinovschi, Andrei eng Review 2019/10/28 Curr Opin Allergy Clin Immunol. 2020 Feb; 20(1):71-79. doi: 10.1097/ACI.0000000000000599"

 
Back to top
 
Citation: El-Sayed AM 2024. The Pherobase: Database of Pheromones and Semiochemicals. <http://www.pherobase.com>.
© 2003-2024 The Pherobase - Extensive Database of Pheromones and Semiochemicals. Ashraf M. El-Sayed.
Page created on 22-11-2024